Revolution Medicines has signed a landmark $2 billion royalty and debt financing deal with Royalty Pharma to support its RAS(ON) inhibitors, including the leading candidate daraxonrasib. This agreement provides Revolution with upfront and milestone-linked capital, bolstering its cash runway well beyond the previously projected 2027 horizon. Revolution’s RAS(ON) platform targets historically undruggable RAS-driven cancers such as pancreatic ductal adenocarcinoma and non-small cell lung cancer. The lead asset daraxonrasib recently entered Phase III trials and gained FDA breakthrough therapy designation for pancreatic cancer. This sizable funding deal ranks among Royalty Pharma’s largest recent industry investments, highlighting confidence in Revolution’s tri-complex inhibitor technology and pipeline versatility.